Drug Approval | March 27, 2024
Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
The company is confident of addressing the concern raised by the USFDA
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
The Cabinet has approved budgetary support of Rs. 2207.50 crore in the 15th Finance Commission Cycle to run CAPFIMS as a campus of AIIMS, New Delhi.
The inspection was concluded with few procedural observations
The company will provide comprehensive response to USFDA for the observations
This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently
Eugia Pharma Specialities restarts production at terminally sterilized product lines
The preventive and promotive approach of our traditional health care systems has played a significant role in modern age today
Subscribe To Our Newsletter & Stay Updated
